Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Februar 2026 07:58 ET | Quelle: Spherix Global Insights

Novo Nordisk’s Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity

Exton, PA, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The obesity treatment landscape continues to evolve rapidly as demand for GLP-1–based therapies remains strong and competition intensifies. Novo...
17. Februar 2026 15:24 ET | Quelle: Spherix Global Insights

Gazyva Establishes Early Clinical Credibility in Lupus Nephritis Three Months Post-Approval, According to Spherix Global Insights

Exton, PA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- – Three months into its U.S. launch for lupus nephritis (LN), Roche/Genentech’s Gazyva (obinutuzumab) is entering a treatment landscape shaped not only...
05. Februar 2026 11:40 ET | Quelle: Spherix Global Insights

Spherix Global Insights Reveals Persistent High Disease Burden and Heavy Reliance on Pain Management in U.S. Sickle Cell Disease Despite Awareness of Disease-Modifying Therapies

Exton, PA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- New research from Spherix Global Insights underscores the profound and multifaceted burden faced by patients living with sickle cell disease (SCD),...
20. Januar 2026 09:17 ET | Quelle: Spherix Global Insights

Rheumatologists Sharpen Differentiation Across the SLE Pipeline as Late-Stage Assets Crystallize into More Defined Clinical Roles, According to Spherix Global Insights

Exton, PA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Updated findings from the Q4 2025 Market Dynamix™: SLE, Pipeline Refresh reveal a maturing and increasingly stratified development landscape, as US...
14. Januar 2026 09:09 ET | Quelle: Spherix Global Insights

Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Exton, PA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights reports new findings from its inaugural Market Dynamix™: PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and...
08. Januar 2026 10:05 ET | Quelle: Spherix Global Insights

New Spherix Patient Research Shows Nearly Half of Atopic Dermatitis Patients Report Major Quality-of-Life Impact Despite Expanding Treatment Options

EXTON, PA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible...
17. Dezember 2025 10:14 ET | Quelle: Spherix Global Insights

UCB’s Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights

EXTON, PA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- New research from Spherix Global Insights shows that the Hidradenitis Suppurativa treatment landscape is entering a period of accelerated change as...
11. Dezember 2025 09:51 ET | Quelle: Spherix Global Insights

Approval of Roche/Genentech’s Gazyvaro Set to Reshape the EU5 Lupus Nephritis Treatment Landscape, According to Spherix Global Insights

EXTON, PA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Following this week’s European Commission approval of Roche/Genentech’s Gazyvaro (obinutuzumab) for the treatment of lupus nephritis (LN), Spherix Global...
09. Dezember 2025 14:44 ET | Quelle: Spherix Global Insights

Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights

EXTON, PA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape. In...
02. Dezember 2025 17:10 ET | Quelle: Spherix Global Insights

Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma

EXTON, PA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- “Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there’s no clear, consistent guidance – ask five academic physicians and...

Nächste Seite